New cocktail shows promise for Hard-to-Treat colon cancer
NCT ID NCT04362839
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This early-phase study tested a combination of three drugs—regorafenib, nivolumab, and ipilimumab—in 39 people with advanced colorectal cancer that had spread and was no longer responding to chemotherapy. The main goal was to find the safest dose and identify side effects. The approach aims to slow tumor growth by both blocking cancer cell signals and boosting the immune system's attack on the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III RECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.